- Home
- DBD vs BHVN Comparison
DBD vs BHVN Comparison
Compare DBD & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- BHVN
- Stock Information
- Founded
- DBD 1859
- BHVN 2013
- Country
- DBD United States
- BHVN United States
- Employees
- DBD N/A
- BHVN N/A
- Industry
- DBD EDP Services
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- BHVN Health Care
- Exchange
- DBD Nasdaq
- BHVN Nasdaq
- Market Cap
- DBD 1.8B
- BHVN 1.9B
- IPO Year
- DBD N/A
- BHVN 2017
- Fundamental
- Price
- DBD $49.96
- BHVN $16.88
- Analyst Decision
- DBD Strong Buy
- BHVN Strong Buy
- Analyst Count
- DBD 2
- BHVN 14
- Target Price
- DBD $65.00
- BHVN $59.85
- AVG Volume (30 Days)
- DBD 140.9K
- BHVN 2.3M
- Earning Date
- DBD 05-07-2025
- BHVN 05-12-2025
- Dividend Yield
- DBD N/A
- BHVN N/A
- EPS Growth
- DBD N/A
- BHVN N/A
- EPS
- DBD N/A
- BHVN N/A
- Revenue
- DBD $3,696,800,000.00
- BHVN N/A
- Revenue This Year
- DBD $2.02
- BHVN N/A
- Revenue Next Year
- DBD $1.96
- BHVN $59.97
- P/E Ratio
- DBD N/A
- BHVN N/A
- Revenue Growth
- DBD N/A
- BHVN N/A
- 52 Week Low
- DBD $34.38
- BHVN $14.33
- 52 Week High
- DBD $51.81
- BHVN $55.70
- Technical
- Relative Strength Index (RSI)
- DBD 65.60
- BHVN 46.71
- Support Level
- DBD $49.15
- BHVN $15.48
- Resistance Level
- DBD $48.94
- BHVN $15.94
- Average True Range (ATR)
- DBD 0.91
- BHVN 0.94
- MACD
- DBD -0.02
- BHVN 0.34
- Stochastic Oscillator
- DBD 85.19
- BHVN 93.18
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.